GLP-1 and metabolic peptide protocols — semaglutide, tirzepatide, retatrutide, AOD-9604. Titration schedules, dose ranges, cycle length, side effects.
Fat-loss peptides fall into two groups: GLP-1 receptor agonists such as semaglutide, tirzepatide, and retatrutide, which act on appetite and gastric emptying, and lipolytic fragments such as AOD-9604. GLP-1 protocols are titrated upward slowly over weeks to limit gastrointestinal side effects.
Protocols covered: Semaglutide, Tirzepatide, Retatrutide, AOD-9604, Tesamorelin, 5-Amino-1MQ.
Semaglutide: 0.25 – 2.4 mg, 1× per week (same day). Cycle: Continuous (titrate up over months); 4-week titration phases. Tirzepatide: 2.5 – 15 mg, 1× per week. Cycle: Long-term; cycle off 4 weeks every 6 months. Retatrutide: 0.5 – 12 mg, 1× per week (every 7 days) AM/PM. Cycle: No strict cycle. Most users transition to a maintenance dose long-term.. AOD-9604: 250 – 1000 mcg, Daily (AM fasted) or split AM/PM. Cycle: 12 weeks on, 4 weeks off. Tesamorelin: 1 – 2 mg, Daily (bedtime). Cycle: 26-week cycles typical; continuous with monitoring. 5-Amino-1MQ: 5 – 15 mg, 1× daily, subcutaneous injection. Cycle: 8–12 weeks on, 4 weeks off.